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ToinvestigatethebiologicaleﬀectofadenosineA2breceptor (A2bR)onthehumanhepatocellularcarcinomacelllineHepG2,three
A2bR siRNA constructs were transiently transfected into HepG2 cells. The results showed that A2bR siRNA reduced the levels of
A2bR mRNA and protein. In order to further detect the function of A2bR, we established a stable hepatocellular carcinoma cell
line (HepG2) expressing siRNA targeting the adenosine A2b receptor. Targeted RNAi signiﬁcantly inhibited tumor cell growth in
vitro, and ﬂow cytometry (FCM) showed that signiﬁcantly more cells expressing A2bR siRNA were in the G0/G1 phase compared
to the untransfected group ((89.56% ± 3.15%) versus (56.19% ± 1.58%), P<0.01). These results indicated that silencing the
expressionofadenosineA2breceptor inHepG2 cells cansuppresscell growtheﬀectively by blockingthecell cycle. Downregulation
of adenosine A2b receptor gene expression with RNA interference could be a new approach to hepatocellular carcinoma therapy.
1.Introduction
Adenosine is an intermediate product of adenine nucleotide
metabolism. In many organs, adenosine is released into the
extracellular space when the oxygen supply is decreased or
energy consumption is increased [1, 2]. In particular, sig-
niﬁcant levels of adenosine are found in the extracellular
ﬂuid of solid tumors, suggesting a role for adenosine in
tumor growth [3]. Adenosine is an endogenous nucleoside
that modulates many physiological processes through its
interaction with at least four membrane receptors: A1, A2a,
A2b, and A3 [4, 5]. The A2 receptors are divided into two
subtypes: high-aﬃnity A2 receptors in rat striatum and low-
aﬃnity A2 receptors throughout the brain [6]. These high-
and low-aﬃnity receptor subtypes were later designated
as A2a and A2b, respectively [7]. The knowledge of A2b
receptors lags behind that of other receptor subtypes. It was
thought that the A2b receptor plays a small role in vivo
because of its relatively low aﬃnity for adenosine. Recently,
Spychala discovered that activation of adenosine receptors
may be involved in tumor progression [8].
In a previous study, we collected 64 samples of hepa-
tocellular carcinoma from clinical patients and found that
A2b receptors were highly expressed in tumor tissue and
expressed in peritumoral tissues to a lesser extent by real-
timePCR,Westernblot,andimmunohistochemical staining.
These results indicate that the A2b receptor may contribute
to hepatic tumor progression and may represent a good
therapeutic target [9].
Inrecentyears,RNAinterference(RNAi)hasbeenwidely
used to study gene expression regulation in mammalian cells
and therapeutic intervention for various diseases including
cancer [10]. In this study, we investigate whether silencing
the A2B gene has an eﬀect on hepatocellular carcinoma.
2.Materialsand Methods
2.1. Vector-Based shRNA Plasmid Constructs. Our vector
is based on the pSilencer 3.1-H1 neo (Hind III/BamHI )
vector (Ambion) which contains the human H1 promoter
and neomycin resistance gene to enable antibiotic selection2 ISRN Oncology
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Figure 1: Plasmid construction. The construction of vectors pSilencer-3.1-H1 neo-1, pSilencer-3.1-H1 neo-2, pSilencer-3.1-H1 neo-3, and
pSilencer-3.1-H1 neo-Y. Hind III and Bam H I were used to digest the vector, and a 64 bp fragment was excised.
in mammalian cells. Three pairs of complementary oligo-
nucleotides (shRNA1, shRNA2, and shRNA3) were synthe-
sized, targeting adenosine A2b receptor cDNA (GenBank:
NM 000676CDS 333–1331) at nucleotides 591–610, 856–
875, and 909–928, respectively. The oligonucleotides encod-
ing the human adenosine A2b receptor shRNA targeting the
adenosine A2b receptor were as follows (http://www.am-
bion.com/techlib/resources/RNAi/index.html).
shRNA 1.
5 -GATCCCGTGCTGGTGATCTACATTAATTCA-
AGAGATTAATGTAGATCACCAGCATTTTTT-
GGAAA-3 
5 -AGCTTTTCCAAAAAATGCTGGTGATCTACA-
TTAATCTCTTGAATTAATGTAGATCACCAG-
CACGG-3 
shRNA 2.
5 -GATCCCGTCCCATTGTCTATGCTTACTTCA-
AGAGAGTAAGCATAGACAATGGGATTTTTT-
GGAAA-3 
5 -AGCTTTTCCAAAAAATCCCATTGTCTATGC-
TTACTCTCTTGAAGTAAGCATAGACAATGG-
GACGG-3 
shRNA 3.
5 -GATCCCGTTATCTCCAGGTATCTTCTTTCA-
AGAGAAGAAGATACCTGGAGATAATTTTTT-
GGAAA-3 
5 -AGCTTTTCCAAAAAATTATCTCCAGGTATC-
TTCTTCTCTTGAAAGAAGATACCTGGAGAT-
AACGG-3 
All oligonucleotides were synthesized by SBS Genetech,
Ltd. The synthesized shRNA cassette was annealed and
cloned into the pSilencer3.1-H1 neo vector according to the
manufacturer’s instructions. A BLAST search with the target
sequences was performed to ensure that only the adenosine
A2breceptorgenewastargeted.Ascrambledcontrolplasmid
(pSilencer-3.1-Y) encoding a shRNA contained a sequence
not present in the mouse, human, or rat genome databases.
The sequence was as follows.
shRNA.
5 -GATCCAGTTCAACGACCAGTAGTCTTCAAG-
AGAGACTACTGGTCGTTGAACTTTTTTTGG-
AAA-3  and
5 -AGCTTTTCCAAAAAAAGTTCAACGACCAGT-
AGTCTCTCTTGAAGACTACTGGTCGTTGAA-
CTG-3 .
2.2. Plasmid Transfection and Establishment of Stable-Ex-
pression Models of Adenosine A2b Receptor in HepG2 Cells.
HepG2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, Gibco), supplemented with 10% heat-
inactivated FBS in a humidiﬁed incubator with 5% CO2
at 37◦C. Cells were transfected with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions
with 8μg pSilencer 3.1-H1 neo-mix (shRNA1, shRNA2, and
shRNA3) and pSilencer-3.1-Y. One day after transfection,
cells were screened in medium containingG418 (0.4mg/mL)
and resistant clones were maintained in medium containing
0.4mg/mL G418. Stably transfected cells were plated in 60-
mm dishes (1.5 × 106 per dish). The results were observed
under the microscope.
2.3. RT-PCR. The treated cells were trypsinized and then
centrifuged for 2 minutes at 12,000rpm at 4◦C. Cell
pellets were washed with PBS, collected, and lysed with
TRIzol reagent (Gibco). Total RNA was isolated by phenol/
chloroform extraction, isopropanol precipitation, and 75%
ethyl alcohol wash and dissolved in DEPC water. The
reverse transcription reaction was set up according to
Promega’s Reverse Transcription System protocol using
primers for the A2b receptor (forward primer: 5 -TCCATC-
TTCAGCCTTCTGGC-3 ; reverse primer: 5 -AAAGGC-
AAGGACCCAGAGGA-3 )a n dβ-actin (forward primer: 5 -
GCCCTGAGGCACTCTTCCA-3 ; reverse primer: 5 -GAA-
GGTAGTTTCGTGGATGCCA-3 ). Each PCR reaction was
performed using an optimized number of cycles (25 cycles)ISRN Oncology 3
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Figure 2: mRNA expression levels of A2b receptor after transient
transfection of the Mix siRNA constructions into HepG2 cell
lines by RT-PCR. Compared to normal controls, transfection
with pSilencer3.1-mix signiﬁcantly reduced the mRNA of the A2b
receptor. The pSilencer3.1-Y did not aﬀect the mRNA level of A2b
receptor. β-actin was ampliﬁed to verify equal loading.
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Figure 3: Protein expression levels of A2b receptor after transient
transfection of the mixed siRNA constructs into HepG2 cell lines.
Compared to normal controls, the pSilencer3.1-mix signiﬁcantly
reduced protein expression of the A2b receptor. The pSilencer3.1-Y
did not aﬀect the protein level of A2b receptor. β-actin was detected
to verify equal loading.
of 94◦Cf o r1m i n u t e ,5 6 ◦C for 30 seconds, and 72◦Cf o r
40 seconds, with a ﬁnal extension of 72◦Cf o r7m i n u t e s .
The PCR reactions were visualized on a 1.2% agarose gel
containing 5μg/mL of ethidium bromide. Intensity of the
DNA bands was analyzed by Glyko BandScan Analysis
software, using β-actin as an internal standard.
2.4. Western Blot. Cell monolayers in six-well culture plates
were washed twice with ice-cold PBS and lysed with 150μL
of RIPA lysis buﬀer (0.05M Tris-HCl (pH 7.4), 0.15M NaCl,
0.25% deoxycholic acid, 1% NP-40, and 1mM EDTA) con-
taining protease inhibitors (1mM PMSF, 1μg/mL aprotinin,
and 1μg/mL leupeptin). Protein concentration was mea-
sured (BCAProteinAssay, Pierce),and samples were resolved
by reducing SDS-PAGE, transferred to nitrocellulose, and
incubated in blocking buﬀer (25mM Tris-HCl, pH 8.0,
125mM NaCl, 0.05% Tween 20, and 5% BSA). Membranes
were incubated with an antibody to the adenosine A2b
receptor (Chemicon International, diluted 1:200) at 4◦C
overnight.The membraneswere washed inblockingsolution
and incubated with an HRP-conjugated secondary antibody
for 1 hour at room temperature. Detection was performed
using the Pierce chemiluminescence HRP substrate accord-
ing to manufacturer’s instructions. Blots were exposed to X-
ray ﬁlm for the appropriate time period.
2.5. Soft Agar Colony Formation Assay. A total of 2 × 102
cells/well were suspended in complete medium containing
0.3% agarose (Gibco) and seeded in triplicate in six-well
plates onto a bottom layer of complete medium containing
0.6% agarose. The plates were cultured for 14 days. Colonies
were counted after methanol ﬁxation and Giemsa staining.
2.6. Flow Cytometry. A total of 50,000 cells were used for
ﬂuorescence-activated cell sorter analysis (FACS).Brieﬂy,the
cells were harvested, washed twice with PBS buﬀer, and
then incubated at room temperature for 45 minutes. After
two PBS washes, the cells were resuspended in PBS and
ﬁltered through Spectra Mesh ﬁlters (Spectrum). Data were
analyzed by CellQuest software (Becton-Dickinson) and the
ModFit/LT software. At total of 20,000 events were acquired
from every sample.
2.7. MTT Assay. HepG2 cells were passed into 96-well plates
(1,000 cells/well) 24 hours after transfection. Viability and
proliferation of cells were measured using MTT assays from
the second until the seventh day after passage. For each
group, 6 wells were measured every day. Experiments were
carriedoutatotalofthreetimes,andthediﬀerenceinaverage
OD (490nm) between treated groups was compared using
the unpaired, two-tailed t-test.
2.8. Statistical Analysis. Statistical analyses were performed
with SPSS11.0 software. Signiﬁcance was evaluated by Stu-
dent’s t-test for paired or independent samples. Results were
expressed as mean ± standard error (SE). Values with P<
0.05 were considered signiﬁcant.
3.Results
3.1. Plasmid Construction. Four pairs of primers were
cloned into pSilencer3.1-H1 neo (Hind III/BamHI )v e c -
tor to construct four interfering vectors: pSilencer3.1-H1
neo-1, pSilencer3.1-H1 neo-2, pSilencer3.1-H1 neo-3, and4 ISRN Oncology
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Figure 4: Inhibition of cell growth by stable transfection of pSilencer3.1-neo-mix vectors. (a) Anchorage-dependent cell growth was
determined by MTT assay.HepG2 cells transfected withpSilencer3.1-neo-mixconstructs inhibitsproliferation.Thex-axisindicates cultured
time period, and the y-axis represents the row OD value. Growth rate of cells transfected with control vector (pSilencer3.1-neo-Y) or
untransfected cells was compared. (b) Anchorage-independent cell growth was measured by the soft agar assay.Data are presented as means
± SEM.
pSilencer3.1-H1neo-Y. Plasmids were veriﬁed bysequencing
(Figure 1).
3.2. Suppression of Adenosine A2b Receptor Expression by the
siRNA Vector. To verify the silencing eﬀectofthethreesiRNA
vectors, we transfected the three vectorpSilencer3.1-H1neo-
1, 2, 3 (mixed) and pSilencer3.1-H1 neo-Y (as control)
into the HepG2 cell line. RT- PCR showed that transfection
of mixed vector could decrease the A2b receptor mRNA
about 66%±5%, while pSilencer3.1-H1 neo-Y had no eﬀect
(Figure 2).
Western blot analysis of A2b receptor was comparable to
the RT-PCR results (Figure 3). Cells transiently transfected
with pSilencer3.1-H1 neo-1, 2, 3 decreased levels of adeno-
sine A2b receptor (about 70% ± 8%). Cells transfected with
pSilencer3.1-H1neo-YhadnoeﬀectonA2breceptorprotein
levels.
3.3. Transfection of pSilencer3.1-neo-mix Inhibits HepG2 Cell
Growth. To assay the potential role of A2b receptor, HepG2
cells were stably transfected. MTT assays were used to inves-
tigate anchorage-dependent growth rates. Equal amounts
of control vector pSilencer3.1-neo-Y were transfected into
HepG2 cell lines. Untransfected cells were used as an addi-
tional control. After seven days in culture, we compared the
proliferation rate of the three groups of cells. A signiﬁcant
diﬀerence was observed after ﬁve days in culture. The cells
transfected with pSilencer3.1-neo-mix showed a signiﬁcant
decrease in the proliferation rate after ﬁve days in culture.
However, cells transfected with pSilencer3.1-neo-Y and un-
transfected cells had similar proliferation rates (Figure 4(a)).
To determine anchorage-independent growth rates, soft
agar assays were carried out. Control-transfected cells show-
ed an average colony forming eﬃcacy of 108 ± 10.7%, com-
pared to untransfected HepG2 cells (= 100%). In contrast,
Table 1: Cell cycle distribution showing the percentage of cells in
G0/G1, S and G2/M phase according to DNA content.
Group N G0/G1 (%) S (%) G2/M (%)
pSilencer3.1-neo-
Mix 38 9 .56 ±0.15 8.28 ±0.95 2.16 ±1.20
pSilencer3.1-neo-Y 3 62.01 ±2.18 29.58 ± 2.31 8.41 ±0.35
Control 3 56.19 ±1.58 38.41 ± 5.92 5.40 ±4.82
stably transfected cells showed a decreased colony forming
ability of 60.33 ± 9.6% compared with HepG2 cells (P<
0.05) (Figure 4 (b)).
3.4. Transfection of pSilencer3.1-neo-mix Induces Cell Cycle
Arrest of HepG2. To explore the mechanism of growth sup-
pression in A2bR-silencing cells, cell cycle analysis was per-
formed. The number of cells in Go/G1 phase was
89.56, 62.01, and 56.19% for the pSilencer3.1-neo-mix,
pSilencer3.1-neo-Y, and untransfected cells, respectively
(Figure 5 and Table 1).
4.Discussion
Liver cancer is the ﬁfth most important cancer worldwide
in terms of morbidity but the third in terms of mortality.
In addition, its mortality has increased in recent years,
with 548,600 cases in the year 2000 [11]. Little is known
about the mechanisms of hepatocarcinogenesis which seem
to diﬀer according to the risk factors involved. Many genes
are associated with livercancer.The p53proteinisinvolvedin
cell cycle control, senescence, DNA repair, genomic stability,
and apoptosis, and diﬀerentmutationsofp53are involvedin
hepatocellular carcinoma formation [12]. The pRB protein
is phosphorylated during the G1 phase of the cell cycle byISRN Oncology 5
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Figure 5: Analysis of cell cycle after silencing the A2b receptor gene in HepG2 cell line. Stably transfected HepG2 cells were prepared for
FACS analysis after 5 days. The pictures show one representative experiment from three total repeats.
members of the cyclin-dependent kinase (CDK) system, and
abrogation of the p16-Rb pathway has been observed in
hepatocellular carcinoma [13]. The mutation of other genes,
including β-catenin [14], SMAD2, SMAD4 [15], p16 INK4a
[16], and Cyclin D1 [17], may also be implicated in liver
cancer.
Adenosine is an endogenous nucleoside that modulates
many physiological processes. Its actions are mediated by
interactionwithspeciﬁc cellmembrane receptors.Adenosine
receptors modulate intracellular levels of adenosine 3 ,5 -
cyclic monophosphate (cAMP). Signiﬁcant advances have
been made in the understanding of the molecular pharma-
cology and physiological relevance of adenosine receptors,
but little is known about A2b receptors. A2b receptors have
been implicated in mast cell activation [18]a n da s t h m a[ 19],
vasodilation [20], regulation of cell growth [21], intestinal
function [22], and modulation of neurosecretion [23]. In
a previous study, we found that A2b receptors were highly
expressed in hepatocellular carcinoma tissue, indicating that
expression of the A2b receptor may contribute to tumor
progression and may be a good therapeutic target for liver
cancer.
RNA interference (RNAi) is a natural silencing process
ﬁrst described in Caenorhabditis elegans and Drosophila mel-
anogaster [24] by which double-stranded RNA initiates and
directs the degradation of homologous mRNA [25]. Speciﬁc
inhibition of cellular mRNA by RNAi can be triggered
in mammalian cells by the introduction of synthetic 21-
to 23-nucleotide double-stranded small interfering RNA
(siRNA) [26, 27] or alternatively by the transcription of
siRNA from a DNA construct driven by the RNA polymerase
cassette [28]. RNAi technology has been widely used as an6 ISRN Oncology
extremely powerful strategy for reverse functional genomics
[29, 30] and as an eﬀective method for gene silencing-based
therapeutics [31, 32]. RNAi-mediated inhibition of virus
infection or replication has been reported for numerous
viruses, including several important human pathogens such
as HIV-1, hepatitis C virus, and Dengue virus [33–35].
RNAi-mediatedoncogenesilencingcanalsoconferresistance
to tumorigenesis [36].
In this study, we constructed three RNAi vectors which
target the A2b receptor gene to investigate if silencing can
convert the tumor phenotype. First, the mixed plasmid
constructs were transiently transfected into HepG2 cells. As
shownbyRT-PCRandWesternblot,transfected cellsshowed
speciﬁc silencingoftheA2breceptorgenewithoutinterrupt-
ing othermolecularinteractions. A stablytransfected HepG2
cell line which silences the expression of A2b receptors was
constructed to observe any changes in phenotype. MTT
and soft agar assays show that the proliferation rate of the
stably transfected cells was signiﬁcantly decreased compared
with control-transfected or untransfected HepG2 cells. FCM
experiments revealed that 89.56 ± 3.15% of stably trans-
fectedcellswerein theG1phase.Takentogether,theseresults
show that RNAi silencing of the A2b receptor gene alters the
phenotype of HepG2 cells, and this method might lead to
developmentofnoveltherapiesforthehumanhepatocellular
carcinoma.
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